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Edward Zammit
In Practice
The Irritable Bowel Syndrome
A 45 year old businessman presents at your clinic with a 
2 year history of recurrent abdominal pain, associated with 
frequent bouts of diarrhoea. The pain is relieved by defaecation, 
but there is often a feeling of incomplete evacuation. Between 
these episodes he is often constipated, with infrequent bowel 
motions characterised by hard stools. During stressful situations, 
symptoms get worse and are associated with abdominal bloating 
and increased flatulence. He researched his problem on the 
internet and thinks he might have Irritable Bowel Syndrome.
Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal 
disorder characterised by abdominal pain and altered bowel 
habits in the absence of specific and unique organic pathology. 
IBS is troublesome, with a significant negative impact on quality 
of life and social functioning in many patients, but it is not 
known to be associated with the development of serious disease 
or with excess mortality. IBS generates significant health care 
costs, both direct, because of IBS symptoms and associated 
disorders, and indirect, because of time off work.
10-15% of the people in Western countries suffer from 
this condition, but only about 30% of affected people see their 
primary care physician about it.1 IBS accounts for 40-60% of 
referrals to gastroenterology outpatient clinics. In Western 
countries, women are 2-3 times more likely to develop IBS than 
men. The difference between the sexes is even more marked in 
IBS consulters in primary care and may be as high as 3 to 4 times 
in secondary care.1  Approximately 50% of people with IBS report 
symptoms beginning before they were aged 35 years and 40% 
of patients develop symptoms between 35 and 50 years of age. 
Onset in elderly persons is rare.2 IBS is recognised in children, 
and many patients can trace their symptoms to childhood. One 
study found that 26% of children with recurrent abdominal 
pain were diagnosed with IBS, making it a common reason for 
school absenteeism.3 
Pathophysiology
The pathogenetic mechanisms of IBS are still poorly 
understood. Traditionally, genes, psychosocial factors, changes 
in gastrointestinal motility and visceral hypersensitivity were 
considered the prime suspects. IBS clearly aggregates within 
families and is more common in stressed, anxious and depressed 
patients. Colonic transit time is shorter in patients with 
diarrhoea and longer than normal in constipation. Patients with 
IBS exhibit evidence of altered CNS processing of visceral pain. 
Recent studies have implicated factors such as dysregulation 
of the brain–gut axis, imbalance in the intestinal microflora, 
gastrointestinal infection and chronic gut inflammation.4   All of 
these factors are thought to contribute, in one way or the other, 
to the general picture.
Clinical Features
These are broadly categorised into gastrointestinal and 
non-gastrointestinal symptoms. The former include recurrent 
Edward Zammit MD
Primary Healthcare Department, Floriana, Malta
Email: edwardzammit@yahoo.co.uk
Keywords
Irritable bowel syndrome, diagnostic criteria, alarm features, 
psychological intervention
Malta Medical Journal    Volume 21   Issue 02   June 2009 35
abdominal pain relieved by defaecation and associated 
with disturbed bowel habit - a change in the appearance 
or frequency of stools. Other associated symptoms include 
bloating, distension, mucus in the stool, urgency, and a feeling 
of incomplete evacuation. The importance of these symptoms 
in the diagnosis of IBS will be discussed later.
Many IBS patients also report non-gastrointestinal 
symptoms that may be due to the coexistence or overlap of IBS 
with another condition such as fibromyalgia, chronic fatigue 
syndrome, or interstitial cystitis such as:
• Fatigue 
• Muscle pain 
• Sleep disturbances 
• Sexual dysfunction 
• Urinary symptoms such as nocturia, frequency and 
urgency of micturition, incomplete bladder emptying.
Other symptoms may occur that tend to correlate with the 
severity of the IBS such as
• Low back pain 
• Headache 
Physical examination is often normal, although non-specific 
abdominal tenderness or a palpable, tender colon may be 
present.5
Four patterns may be seen with irritable bowel syndrome. 
These patterns include IBS-D (diarrhoea predominant), 
IBS-C (constipation predominant), IBS-M (mixed diarrhoea 
and constipation), and IBS-A (alternating diarrhoea and 
constipation). These patterns are mentioned in the Rome II 
criteria, but their usefulness is debatable.
Diagnosis
Traditionally, IBS is a diagnosis of exclusion, based on 
history, physical examination, and a negative battery of 
diagnostic studies. There are no structural or chemical markers 
for IBS.6 Diagnostic tests are frequently overused because 
physicians are concerned about missing a life-threatening 
illness.7
The diagnosis of IBS should be one that is based on 
positive findings rather than a diagnosis made after extensive 
investigation to exclude other disorders. Because there is no 
physiologic marker for the disease, symptom criteria have been 
developed to encourage diagnosis through history taking and to 
standardise patients entered into clinical trials. 
The most common criteria used in research and clinical 
practice are the 2006 Rome III diagnostic criteria for IBS, 
summarised in Table 1. They require symptoms to have 
originated 6 months prior to diagnosis and be currently 
active (i.e. meet criteria) for 3 months. Abdominal pain is the 
main indicator and other cumulative symptoms support the 
diagnosis.8 These criteria have replaced the outdated Manning 
criteria (Table 1), in which the presence of 3 or more criteria 
discriminates IBS from organic gastrointestinal disease, with 
a sensitivity of 58%-81% and a specificity of 67%-87%.9 The 
greater the number of symptoms present, the more likely the 
diagnosis of IBS.8 However the Manning criteria are widely 
considered to be insensitive and less reliable in men.9 In 
addition, abdominal pain does not always overlap with bowel 
habit disorders, unlike the Rome criteria.
The addition of alarm features (Table 2) to symptom criteria 
seems to enhance diagnostic accuracy.10 Recent studies have 
demonstrated that the absence of alarm symptoms increases 
the positive predictive value of the criteria.13
Furthermore, there is evidence that the addition of non-
colonic and even non-gastrointestinal symptoms can also 
improve diagnostic accuracy.14
Other helpful clues to the diagnosis of IBS are that the 
symptoms are chronic or recurrent, the pain is variable in 
location and timing, diarrhoea and constipation may alternate, 
the onset sometimes follows infectious gastroenteritis, and the 
symptoms may be related to stress.15-17
Differential Diagnosis 
Many illnesses share some of the same symptoms as IBS. 
Some of these illnesses are serious and require aggressive 
evaluation and treatment. The differential diagnosis for patients 
who present with abdominal pain and altered bowel habits is 
summarised in Table 3.
A careful and detailed history and physical examination 
are needed to establish diagnostic criteria, and take note 
of supporting symptoms and alarm features. As regards 
investigations in the primary care setting, the issue becomes 
hazier.
The NICE Guidelines18 recommend that in people who 
meet the IBS diagnostic criteria, the following tests should be 
undertaken to exclude other diagnoses:
•  Full blood count (FBC)
•  Erythrocyte sedimentation rate (ESR) 
•  C-reactive protein (CRP)
•  Antibody testing for coeliac disease (endomysial 
antibodies [EMA] or tissue transglutaminase antibodies 
[TTG]).
They go on to recommend that the following tests are not 
necessary to confirm diagnosis in people who meet the IBS 
diagnostic criteria:
•  Ultrasound
•  Rigid/flexible sigmoidoscopy
•  Colonoscopy; barium enema
•  Thyroid function test
•  Faecal ova and parasite test
•  Faecal occult blood
•  Hydrogen breath test (for lactose intolerance and 
bacterial overgrowth).
On the other hand, patients who present with alarm 
features during the history, physical examination and basic 
investigations, should be immediately referred to secondary 
care. The emergence of any alarm features during management 
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Table 1: The Manning and Rome III criteria
Manning Criteria
1.  Onset of pain linked to more frequent bowel 
movements
2.  Looser stools associated with onset of pain
3.  Pain relieved by passage of stool
4.  Noticeable abdominal bloating
5.  Sensation of incomplete evacuation more than 25% of 
the time. 
6.  Diarrhoea with mucus more than  25% of the time 
Factor analysis shows the first three symptoms correlate 
well but are not  related to 4, 5 and 6.11  4  is more useful in 
women, as abdominal bloating is less common in men.12
Rome	III	Criteria
The Rome III criteria (2006) require that patients must 
have recurrent abdominal pain or discomfort at least 3 days 
per month during the previous 3 months that is associated 
with 2 or more of the following:
1. Relieved by defaecation 
2. Onset associated with a change in stool frequency
3. Onset associated with a change in stool form or 
appearance
Supporting symptoms include the following:
4. Altered stool frequency (greater than 3 bowel 
movements/day or less than 3 bowel movements/week)
5. Altered stool form (lumpy/hard or loose/watery stool)
6. Altered stool passage (straining and/or urgency)
7. Mucorrhoea
8. Abdominal bloating or subjective distention.
In pathophysiology research and clinical trials, 
a pain/discomfort frequency of at least 2 days
a week during the screening evaluation is 
recommended for subject eligibility.
Table 2:  Alarm features in irritable bowel syndrome
History
 • New onset of symptoms in patient > 50 years
 • Short history of symptoms
 • Documented weight loss (unexplained and 
unintentional)
 • Nocturnal symptoms
 • Male sex
 • Family history of colon cancer (and other 
gastrointestinal cancers)
 • Anaemia
 • Rectal bleeding
 • Recent antibiotic use
 • Persistent diarrhoea 
 • Severe constipation
 • Fever
 • Inflammatory bowel disease or coeliac disease
 • Travel history to locations with endemic parasitic 
diseases
Examination
• Fever 
 • Abdominal masses
 • Rectal masses
 
Investigations
• Anaemia on full blood 
count
• Positive inflammatory 
bowel disease markers.
and follow-up of patients diagnosed with IBS should prompt 
further investigation and/or referral to secondary care.
The British Society of Gastroenterology guidelines 
recommend a FBC in all older patients at first presentation 
a FBC and ESR/CRP in all those with new IBS-D. Testing for 
coeliac disease in IBS-D is only considered cost-effective if the 
incidence of coeliac disease in that population is above 1%19 (it 
is estimated to be 1% in the Maltese population).20 Other tests, 
including the faecal occult blood test, are not recommended as 
first line investigations.
Coeliac disease
It should be noted that testing for coeliac disease is 
recommended as a first line test, alongside other less specific 
investigations. This stems from the diagnostic difficulty one 
often encounters in trying to distinguish between the two. Many 
of the symptoms found in IBS are shared by coeliac disease. 
In addition, several studies suggest that screening for coeliac 
disease in IBS patients, even in a population with relatively low 
coeliac disease prevalence and small improvements in quality 
of life with a gluten-free diet, is still cost-effective.21
Management 
Since the aetiology of IBS is still obscure, its management is 
still mainly symptomatic, with attempts at dealing with potential 
underlying disorders in stress responsiveness, and predisposing 
psychological features. To make matters worse, the different 
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IBS patterns, with their own predominant symptoms, often 
warrant a combination of different treatment modalities. The 
efficacy of several of these modalities is still in question. They 
can be broadly classified into these categories: Diet and lifestyle, 
Pharmacological, Psychological and Psychosocial interventions, 
and Complementary therapies.
Diet	and	Lifestyle	(Table	4)
Many patients with IBS believe that their symptoms are 
caused by food, and so they expect a dietary solution. Some 
exclude many foods with little evidence of improvement. 
Unfortunately, there is scanty scientifically valid information 
on the relation of diet to IBS symptoms, especially as regards 
food allergies and intolerances.22 Data from dietary elimination 
and food challenge studies are contradictory, and in some 
cases inconclusive. The fact remains that food intolerances 
are often present in patients with IBS, as well as in the general 
population, and their symptoms closely mimic those of IBS. 
Common culprits include milk (lactose), wheat, eggs, nuts, 
shellfish, caffeine and soybeans. A trial of exclusion and serial 
reintroduction of individual foods can be done to detect co-
existing food intolerances.23 Dietary exclusion can then be done, 
under the supervision of a qualified dietician, to deal with the 
intolerance, irrespective of its causal relationship with IBS, 
thus reducing the overall symptoms, while taking care to avoid 
malnutrition. Dietary management of food intolerances thus 
is an adjunct of IBS treatment, but it must be tailored to the 
individual, and be done under the guidance of a dietician.24
Fibre
An increase in fibre is often recommended in IBS, but 
there are few data to support this approach. A survey based 
on secondary care patients actually suggested that cereal fibre 
makes the symptoms worse in around 55% of cases, with only 
11% reporting any benefit. Though insoluble fibre (eg. bran, 
green vegetables, sprouts, legumes, seeds, and nuts) helps 
constipation-predominant IBS, current guidelines recommend 
reduced intake of wholemeal or high-fibre flour and breads, 
cereals high in bran, and whole grains such as brown rice. When 
fibre is needed, foods rich in soluble fibre (rice, barley, soy, 
carrots, etc.) or and/or ispaghula powder should be encouraged, 
as it relieves both diarrhoea and constipation.18
Other dietary considerations
Fluid intake (together with soluble fibre) must be increased 
to compensate for the water lost in diarrhoea and to help relieve 
constipation. Caffeine intake should be restricted, because of 
its dehydrating and stimulant effects. Carbonated beverages 
exacerbate bloating and diarrhoea (sorbitol).
Table 4:  Lifestyle: diet and physical activity
Assess diet and nutrition and give general advice  • 
(Table 5 )
Assess physical activity levels, ideally using the General • 
Practice Physical Activity
Questionnaire (GPPAQ).• 
Give people with low activity levels advice and • 
counselling to increase
their activity.• 
Provide information about self-help covering lifestyle, • 
physical activity, diet and
symptom-targeted medication.• 
Encourage people to identify and make the most of their • 
leisure time and to
create relaxation time.• 
 If the person wants to try probiotics, advise them to take • 
the dose recommended
by the manufacturer for at least 4 weeks while • 
monitoring the effect.
Discourage use of aloe vera for IBS.• 
Adapted from NICE guidelines18
Table 3:  Differential diagnosis
IBS with diarrhoea
Dietary - lactose, sorbitol, fructose, caffeine, alcohol, • 
fatty foods, fat substitutes, gas-producing foods 
Infections — Giardia species, Amoeba species, HIV-
related, bacterial overgrowth
IBD — Crohn’s disease, ulcerative colitis, microscopic • 
colitis
Drug toxicity — antibiotics, PPIs, NSAIDs, ACE • 
inhibitors, beta-blockers, chemotherapy
Malabsorption — coeliac disease, bile acid-related• 
Other — ovarian cancer, endometriosis, colorectal • 
cancer, hyperthyroidism, carcinoid, VIPoma, ischaemic 
colitis
IBS with constipation
Dietary/mode of life — inadequate fibre, immobility• 
Neurologic — Parkinson’s disease, multiple sclerosis, • 
spinal cord injuries
Endocrine — diabetes, hypothyroidism, hypercalcemia• 
Drug toxicity — opiate analgesics, calcium-channel • 
blockers, antidepressants, clonidine
Other — colorectal cancer, ovarian cancer, bowel • 
obstruction, diverticular disease, endometriosis
Abbreviations: PPIs: proton pump inhibitors; 
NSAIDs: non-steroidal anti-inflammatory drugs; ACE: 
angiotensin converting enzyme
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Exercise
Current guidelines advise an increase in physical activity in 
patients with low activity levels. Again, studies regarding this 
issue are few and inconclusive, and it is still doubtful whether 
exercise has any effect at all on bowel movements, even in the 
general population.25 Having said that, the benefits of exercise 
on health in general are indisputable, so that regular exercise 
should still be recommended to patients.
Probiotics
There is a growing amount of evidence showing that some 
probiotics are effective in relieving various IBS symptoms, 
especially abdominal pain and bloating. There is no general 
consensus about the best ones. Nevertheless all the studies 
agree that none of them cause any adverse effects.26 Current 
guidelines leave the choice of probiotic use to the patient, with 
the proviso that it is taken at the recommended dose for at least 
4 weeks, while monitoring its effect.
Aloe Vera
Aloe Vera, though not commonly prescribed, is often bought 
by IBS patients, with variable results. Studies have been unable 
to definitely prove its effectiveness in IBS, while proving that 
it can cause serious side effects.27 As a result, its use in IBS is 
often discouraged.
Pharmacological interventions
First-line treatment
Antispasmodics
Antispasmodics help alleviate the pain, which is always 
present at some point and despite doubts about their efficacy, 
several studies have confirmed their efficacy in dealing not only 
with pain, but also with symptoms in general, by reducing the 
exaggerated gastro-colonic reflex.28 It is recommended that they 
are taken 30-45 minutes before a meal.
Laxatives
These are obviously the agents of choice in dealing with 
constipation. The studies available involve patients with acute or 
chronic constipation of different causes, rather than just IBS-C. 
Polyethylene glycol based laxatives emerged as the most effective 
and well tolerated laxatives in chronic constipation (better than 
ispaghula husk, which in turn, is better than lactulose).29-31 The 
use of lactulose is not recommended.18 Stimulant laxatives 
(eg. docusate sodium, glycerol, senna) act erratically and are 
associated with tachyphylaxis and dependency. Stimulants are 
therefore generally recommended only for occasional use.
Antimotility agents
Loperamide is the most popular agent of this class. It reduces 
diarrhoea in patients with IBS-D32  but has little effect on 
abdominal pain.33 Tachyphylaxis does not develop with chronic 
dosing and it is not associated with confusion or anticholinergic 
side effects (as in cophenotrope), or nausea and dysphoria 
(codeine phosphate).34 It is important to teach patients how to 
titrate its dose according to stool consistency, aiming to get a 
soft, well formed stool.
Second-line treatment
Antidepressants
The NICE guidelines recommend moving on to tricyclic 
antidepressants (TCAs) or SSRIs if fist-line treatments do not 
help. The idea here is to use them as analgesics, (rather than 
anti-depressants) so low initial doses are advised (5–10 mg 
equivalent of amitriptyline).35 TCAs should be used first, starting 
at a low dose, taken once at night (because of sedation and to 
aid compliance), with follow up after 4 weeks, increasing dose 
as needed.36  It should be continued for 6 to 12 months, during 
which careful monitoring of side effects should be done, and 
after which dose tapering may be attempted.36  If TCAs are 
ineffective, selective serotonin re-uptake inhibitors (SSRIs) are 
used as they are effective in improving general well-being (but 
not bowel symptoms or pain).37
Psychological Interventions
Anxiety and depression are common in IBS and patients 
report a close relation between stress and their gut symptoms, 
providing a pragmatic rationale for psychological therapy.
Relaxation training is useful when stress causes exacerbation 
of symptoms, which can be relieved by progressive muscle 
relaxation, biofeedback, and transcendental or yoga 
meditations.38 The evidence for the efficacy of cognitive 
behavioural therapy remains controversial.39 One study in 
particular suggests that CBT may help patients cope with their 
Table 5: General dietary advice
Regular meals, at frequent intervals.• 
≥8 cups of fluid per day, especially water or other non-• 
caffeinated drinks such as herbal teas.
≤ three cups  of tea and coffee per day • 
Reduce intake of alcohol and fizzy drinks.• 
Fibre : Reduce intake of insoluble fibre (for example, • 
wholemeal or high-fibre flour and breads, cereals high in 
bran, and whole grains such as brown rice). If more fibre 
is needed (constipation, wind and bloating), take soluble 
fibre such as ispaghula powder, or foods high in soluble 
fibre (for example, oat cereals or porridge) and linseeds 
(up to one tablespoon per day).
Reduce intake of ‘resistant starch’, often found in • 
processed or re-cooked foods.
Limit fresh fruit to three portions (of  80g each) per day.• 
For diarrhoea, avoid sorbitol, found in sugar-free sweets • 
(including chewing gum) and drinks, and in some 
diabetic and slimming products.
Adapted from NICE guidelines18
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symptoms without necessarily abolishing them.39 The evidence 
for hypnotherapy is more compelling, showing that it improves 
many of the features of the condition, including quality of 
life and psychological status.40 The beneficial effects appear 
to be sustained over time, with patients reporting continued 
relief from symptoms for at least five years.41 Psychodynamic 
interpersonal therapy (PIT) may lead to significant life changes 
as well as to an improvement in emotional state and IBS 
symptoms.42 Current guidelines recommend these psychological 
interventions in refractory IBS which does not respond to first-
line pharmacological treatment after 12 months.
Complementary therapies
Despite limited evidence favouring the use of complementary 
therapies, they are becoming increasingly popular in developed 
countries, especially in chronic conditions refractive to 
conventional medicine. Very few complementary disciplines 
have been studied regarding their use in IBS; the three main 
ones being reflexology, acupuncture and herbal medicine. 
Studies on the first two conclude that there is nothing to 
suggest any specific benefit for patients with IBS43,44 and they 
should not be recommended in IBS, pending further studies.18 
Herbal medicine involves the use of a wide variety of herbal 
preparations in different combinations, thus making practice 
recommendations difficult. The evidence available suggests 
that some herbal preparations are effective in some people45, 
but guidelines steer clear from general conclusions and further 
studies are still awaited.
The Role of the GP
The general practitioner is the patient’s first point of 
contact, and in most cases, the one who has been dealing with 
the patient’s problems for years. The onus is on him/her to 
diagnose this condition accurately and with certainty, so that 
management can be initiated as soon as possible and without 
undue investigations and referrals. Once the diagnosis is made, 
the GP should offer help not only in the form of medication, but 
also by providing lifestyle advice, referral to support groups, and 
sources of patient information. Unfortunately, there are no local 
IBS support groups, but plenty of online ones where one can 
interact with other IBS sufferers and share experiences.46 In this 
way the patient will share the responsibility of his management 
with his/her GP, enabling him to cope more effectively with 
his symptoms and improve his quality of life, while reducing 
referrals to secondary care.47 Having said that, the GP should 
be familiar with the alarm features which warrant immediate 
referral to secondary care, even after a confident diagnosis of 
IBS is made.
Returning to our businessman, a careful history and 
examination should be done to confirm or exclude IBS. If 
alarm features are present, immediate referral to secondary 
care is advised. If none are present, the basic blood tests 
mentioned before, should be carried out. If IBS is confirmed, 
antispasmodics should be used to alleviate the pain, while 
using laxatives and antimotility agents, depending on the 
particular pattern exhibited at the time. A trial of probiotics can 
be prescribed, while psychological intervention and self help 
advice can help him deal with stress and improve his quality of 
life. Regular review of the patient is recommended, not only to 
monitor response to treatment, but also to reinforce lifestyle 
modifications and use the consultation as an ongoing therapeutic 
intervention to assist him in coping with the symptoms and 
optimize his social functioning and quality of life. Initially a once 
weekly appointment can be scheduled. Follow-up appointments 
are adjusted according to response.
 
Conclusion
For a long time now, this condition has been relegated 
to the ranks of the functional bowel disorders, which are 
only diagnosed by exclusion. Its consequences are often 
underestimated, because it is not a ‘life-threatening illness’ 
and doctors often heave a sigh of relief once they diagnose 
IBS, as if it is of no consequence. The truth is that this can be 
a debilitating disease leading to distress, frustration, severe 
anxiety and in some cases, social isolation. As such it should be 
treated with respect.
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